Abstract
Cholecystokinin is the most important stimulant of postprandial gallbladder contraction, and a regulator of gallbladder fasting tone. The aim of this study was to evaluate the effect of dexloxiglumide on isolated human gallbladder contraction induced by cholecystokinin–octapeptide and to compare this effect to that of lorglumide and amiglumide, two glutaramic acid analogs of dexloxiglumide. The negative logarithms of the antagonist dissociation constant (pKB) values were 7.00 ± 0.14, 6.95 ± 0.11, and 6.71 ± 0.10 for lorglumide, dexloxiglumide, and amiglumide, respectively. Dexloxiglumide produced a concentration-dependent rightward shift of the cholecystokinin–octapeptide curve, without affecting its maximal response. A similar effect was obtained both with lorglumide and amiglumide. Moreover, the slopes for the three antagonists did not differ significantly from unity. These data show that the three molecules have a potent antagonistic effect, of a competitive nature, on gallbladder cholecystokinin type 1 receptors. It may be concluded that dexloxiglumide, lorglumide, and amiglumide exhibit a promising therapeutic profile for biliary colic and other gastrointestinal disorders in which CCK1 receptors play important physiological roles.
Similar content being viewed by others
References
Watson S, Abbot A: Receptor nomenclature supplement. Trends Pharmacol Sci 11 (suppl):1–30, 1990
Crawley JN, Corwin6RL: Biological actions of cholecystokinin. Peptides 15:731–755, 1994
Hahne WF, Jensen RT, Lemp GF, Gardner JD: Proglumide and benzotrip: Members of a different class of cholecystokinin receptor antagonist. Proc Natl Acad Sci USA 78:6304–6308, 1981
Makovec F, Chistè R, Bani M, Chistè R, Revel L, Setnikar I, Rovati AL: New glutamic and aspartic derivatives with potent CCK-antagonistic activity. Eur J Med Chem 21:9–20, 1986
Makovec F, Bani M, Chistè R, Revel L, Rovati LC, Rovati LA: Differentiation of central and peripheral cholecystokinin receptors by new glutaramic acid derivatives with cholecystokinin-antagonistic activity. Arzneim-Forsch 36:98–102, 1986
Setnikar I, Bani M, Cereda R, Chistè R, Makovec F, Pacini MA, Revel L, Rovati LC, Rovati LA: Pharmacological characterization of a new potent and specific non polypeptidic cholecystokinin antagonist. Arzneim-Forsch 37:703–707, 1987
Makovec F, Chistè R., Peris W, Rovati L: Derivatives of (R)-5–penthylamino-5–oxopentanoic acid with anticholecystokinin activity. European Patent No. 344184, 1988
Scarpignato C, Kisfalvi I, D'Amato M, Varga G: Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: Evaluation of their receptor selectivity in vivo. Aliment Pharmacol Ther 10:411–419, 1996
Varga G, Kisfalvi K, Pelosini I, D'Amato M, Scarpignato C: Different actions of CCK on pancreatic and gastric growth in the rat: Effect of CCKA receptor blockade. Br J Pharmacol 124:435–440, 1998
Varga G, Kisfalvi K, D'Amato M, Scarpignato C: Effect of a new CCK-A receptor antagonist, dexloxiglumide, on the exocrine pancreas in the rat. J Physiol 91:257–264, 1997
Liddle RA, Gertz BJ, Kanayama S, Beccaria L, Coker LD, Turnbull TA, Morita ET: Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in human. Implications for the physiology of CCK. J Clin Invest 84:1220–1225, 1989
Konturek JW, Konturek SJ, A Kurek A, Bogdal J, Oleksy J, Rovati L: CCK receptor antagonism by loxiglumide and gallbladder contractions response to cholecystokinin, sham feeding and ordinary feeding in man. Gut 30:1136–1142, 1989
Revel L, Mennuni L, Garofalo P, Makovec F: CR 2945: A novel CCKB receptor antagonist with anxiolytic-like activity. Behav Pharmacol 9:183–194, 1998
Lennon F, Feeley TM, Clanacan AS, Scott GV: Effects of histamine receptors stimulation on diseased gallbladder and cystic duct. Gastroenterology 87:257–262, 1984
Messa C, Maselli MA, Cavallini A, Caruso ML, Pezzolla F, Di Leo A: Sex steroid hormone receptors and human gallbladder motility in vitro. Digestion 46:214–219, 1990
Arunlakshana O, Shild HO: Some quantitative uses of drug antagonists. Br J Pharmacol Chemother 14:48–58, 1959
Kenakin TP: Pharmacologic Analysis of Drug-Receptor Interaction. Raven Press, New York, 1987
Bitar KN, Maklouf GM: Receptors on smooth muscle cells: characterization by contraction and specific antagonists. Am J Physiol 242:G400–G407, 1982
Revel L, Makovec F, Castaner J: Dexloxiglumide. Drugs Future 24(7):725–728, 1999
Meier R, Beglinger C, Giacovelli G, D'Amato M: Effect of the CCK-A receptor antagonist Dexloxiglumide on postprandial gallbladder emptying and colonic transit time in healthy volunteers. Gastroenterology 106:A538, 1994
Niderau C, Heintges6T, Rovati LC, Strohmeyer G: Effects of Loxiglumide on gallbladder emptying in healthy volunteers. Gastroenterology 97:1331–1336, 1989
Lieverse RJ, Jansen JBM, Jebbink MCW, Masclee AAM, Rovati LC, Lamers CBHW: Effects of somatostatin and loxiglumide on gallbladder motility. Eur J Clin Pharmacol 47:489–492, 1995
Makovec F, Bani M, Cereda R, Chistè R, Pacini6MA, Revel L, Rovati LA, Rovati LC: Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Arzneim-Forsch/Drug Res 37:1265–1268, 1987
D'Amato M, Stamford IF, Bennet A: Studies of three nonpeptide cholecystokinin antagonists (devazepide, lorglumide and loxiglumide) in human isolated alimentary muscle and guinea pig ileum. Br J Pharmacol 102:391–395, 1991
Makovec F, Mennuni L, Peris W, Revel L, Rovati6LC: Biological properties of (R)-4–benzamido-5–oxopentanoic basic derivatives as CCK-antagonists. Bioorg and Med Chem Lett 36(5):861–866, 1993
Gully D, Frehel D, Marcy C, Spinazze A, Lespy L, Neliat G, Maffrand JP, LeFur G: Peripheral biological activity of SR 27897: A new potent nonpeptide antagonist of CCKA receptor. Eur J Pharmacol 232:13–19, 1993
Chang RSL, Lotti VJ, Cheng TB, Kunel KA: Characterization of the binding of [3H](±) L364,718: A new potent nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors. Mol Pharmacol 30:212–217, 1986
Ito H, Sogabe H, Nakarai T, Sato Y, Tomoi M, Kadowaki M, Matsuo M, Tokoro K, Yoshida K: Pharmacological profile of FK 480, a novel cholecystokinin type-A receptor antagonist: Comparison to Loxiglumide. J Pharmacol Exp Ther 268:571, 1994
Hull R, Shenkley NP, Harper EA, Gerskowitch VP and Black JW: 2–Naphthalenesulphonyl L-aspartyl-(2–phenethylamide) (2–NAP)–a selective cholecystokinin CCKA-receptor antagonist. Br J Pharmacol 108:734–740, 1993
Beglinger C, Dill S, Meyer B, Werth B, Adler G: Treatment of biliary colic with loxiglumide. Lancet 2(8655):167, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Maselli, M., Piepoli, A., Pezzolla, F. et al. Effect of Three Nonpeptide Cholecystokinin Antagonists on Human Isolated Gallbladder. Dig Dis Sci 46, 2773–2778 (2001). https://doi.org/10.1023/A:1012748017709
Issue Date:
DOI: https://doi.org/10.1023/A:1012748017709